Biotech · Private company
Clovis Oncology, Inc.
Track this companyFree. Adds Clovis Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials254 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Pemetrexed or gemcitabine or paclitaxel or docetaxelPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- RociletinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LucitanibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LucitanibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LucitanibPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RociletinibPhase 2 · Locally Advanced or Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286PHASE1 · COMPLETED · started Dec 9, 2021ClinicalTrials.gov NCT05180162 · fetched Nov 12, 2026
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyPHASE1_PHASE2 · WITHDRAWN · started Apr 15, 2021ClinicalTrials.gov NCT04151563 · fetched Nov 12, 2026
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 5, 2020ClinicalTrials.gov NCT04624178 · fetched Nov 12, 2026
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 3, 2020ClinicalTrials.gov NCT04253262 · fetched Nov 12, 2026
- Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaPHASE1_PHASE2 · UNKNOWN · started Jan 9, 2020ClinicalTrials.gov NCT03995017 · fetched Nov 12, 2026
- Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaPHASE2 · COMPLETED · started Sep 4, 2019ClinicalTrials.gov NCT03958045 · fetched Nov 12, 2026
- Pan Tumor Rollover StudyPHASE2 · RECRUITING · started Aug 9, 2019ClinicalTrials.gov NCT03899155 · fetched Nov 12, 2026
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorPHASE1_PHASE2 · SUSPENDED · started Jul 29, 2019ClinicalTrials.gov NCT04042116 · fetched Nov 12, 2026
- The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)PHASE2 · COMPLETED · started Jul 19, 2019ClinicalTrials.gov NCT03694262 · fetched Nov 12, 2026
- Rucaparib in Nonmetastatic prOstAte With BRCAnessPHASE2 · TERMINATED · started May 20, 2019ClinicalTrials.gov NCT03533946 · fetched Nov 12, 2026
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerPHASE2 · COMPLETED · started Mar 6, 2019ClinicalTrials.gov NCT03617679 · fetched Nov 12, 2026
- Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerPHASE1_PHASE2 · TERMINATED · started Dec 24, 2018ClinicalTrials.gov NCT03559049 · fetched Nov 12, 2026
- Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsPHASE2 · COMPLETED · started Sep 10, 2018ClinicalTrials.gov NCT03413995 · fetched Nov 12, 2026
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerPHASE1 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT03552471 · fetched Nov 12, 2026
- Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumPHASE2 · COMPLETED · started Jun 29, 2018ClinicalTrials.gov NCT03476798 · fetched Nov 12, 2026
- A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyPHASE1 · COMPLETED · started May 23, 2018ClinicalTrials.gov NCT03542175 · fetched Nov 12, 2026
- An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerPHASE2 · COMPLETED · started Dec 19, 2017ClinicalTrials.gov NCT03338790 · fetched Nov 12, 2026
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerPHASE2 · COMPLETED · started Nov 29, 2016ClinicalTrials.gov NCT02935634 · fetched Nov 12, 2026
- A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 10, 2016ClinicalTrials.gov NCT02873962 · fetched Nov 12, 2026
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyPHASE3 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02322281 · fetched Nov 12, 2026
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerPHASE2 · TERMINATED · started Sep 9, 2014ClinicalTrials.gov NCT02202746 · fetched Nov 12, 2026
- Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung CancerPHASE2 · TERMINATED · started Jun 16, 2014ClinicalTrials.gov NCT02147990 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsPHASE2 · TERMINATED · started Apr 1, 2014ClinicalTrials.gov NCT02109016 · fetched Nov 12, 2026
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsPHASE1_PHASE2 · TERMINATED · started Mar 27, 2012ClinicalTrials.gov NCT01526928 · fetched Nov 12, 2026
- PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsPHASE2 · COMPLETED · started Feb 1, 2010ClinicalTrials.gov NCT01074970 · fetched Nov 12, 2026